LDL Test Market Size was valued at USD 8.40 Billion in 2023. The LDL Test industry is projected to grow from USD 9.02 Billion in 2024 to USD 15.86 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.44% during the forecast period (2024 - 2032). LDL is also mentioned as bad cholesterol since high levels of LDL results in cholesterol build-up which may lead to heart attack and strokes. LDL is one of the five major types of lipoproteins and other four are chylomicrons, very low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), low-density lipoprotein (LDL) and high-density lipoprotein (HDL). The major role of lipoprotein particles is to transport fats such as triglycerides and cholesterol in the blood between the organs of the body.
According to Centres for Disease Control and Prevention, (2015) 71 million American adults have high low-density lipoprotein (LDL), or bad cholesterol level. Only 2 out of every 3 adults with LDL cholesterol has the condition under control.
November 2023:
Primary Healthtech, an Indian Institute of Technology (IIT) Guwahati alumni-led startup, has introduced a novel point-of-care testing (POCT) apparatus. This indigenous technology is anticipated to analyze 25 blood parameters for the early detection of chronic diseases caused by malfunctions of the kidneys, liver, heart, and pancreas.
MobilabTM is an Internet of Things (IoT)-enabled device that can be controlled via an Android application in order to complete approximately 150 tests on a single battery charge. Tuesday, October 10, Sahil Jagnani, chief executive officer (CEO) of Primary Healthtech, stated that the device's viability extends to the most remote regions of the country due to its support from a digitally interconnected ecosystem.
Recent World Health Organization reports indicate that non-communicable diseases (NCDs) account for approximately 41 million (74%) fatalities worldwide. It is anticipated that the device will conduct early screening for these conditions.
"The vision of MobilabTM is to make diagnosis available to fellow citizens at an affordable cost, along with generating instant results to speed up the early screening, disease management, and treatment," according to Jagnani.
Additionally, he stated that MobilabTM is anticipated to fulfil import substitution as part of the Make-in-India initiative of the Central government. Moreover, it will facilitate low-cost testing at the patient's location, facilitating long-term disease management and early detection.
Government laboratories accredited by the National Accreditation Board for Testing and Calibration Laboratories (NABL) have validated eleven parameters. These parameters include total protein, total bilirubin, albumin, and cholesterol for the heart profile; creatinine, glucose, and uric acid for the kidney profile; haematology, haemoglobin, and diabetic in glucose for the hepatic profile.
The device produces data within a duration of ten minutes. Subsequently, a digital report and the patient's electronic health record are generated, facilitating seamless sharing with medical professionals.
A January 2024 report indicates that India has just unveiled an innovative drug claimed to have the potential to lower low-density lipoprotein (LDL-C) cholesterol, commonly known as "bad” blood cholesterol, which is responsible for heart attacks and strokes. Inclisiran by Novartis- a Swiss pharmaceutical industry giant-could change how atherosclerotic cardiovascular disease is managed according to findings from a Jan. 2024 report.
On September 2023, ACC initiated the 'Driving Urgency in LDL Screening' Quality Improvement Campaign with Amgen and Esperion in order to increase diagnostic rates of LDL screening among patients without prior cardiac events and known cardiovascular diseases by physicians who will then assess whether their patients meet treatment criteria based on medical guidelines.
This indicated that new PCSK9 inhibitors given quarterly lowered LDL-cholesterol levels by more than 50% versus placebo on top of other lipid-lowering medications among those already taking them, according to a report done in November 2023. This was evidenced by the REMAIN-2 clinical study.
The market drivers for LDL Test Market are increasing geriatric population, increasing obese and overweight population. The major market restraints for this test are risks associated with this such as excessive bleeding and infection during multiple puncture wounds, low healthcare expenditure in developing regions which may hamper the market growth.
Intended Audience
The LDL test market has been segmented on the basis of types, components, applications and end users.
Based on types, the market has been segmented into LDL-C, LDL-P, LDL-B and others.
Based on components, the market has been segmented into devices, kits & reagents and others. Devices is further sub-segmented into syringes & needles, spectrophotometers and others. And kits & reagents is further sub-segmented into toxicity assays kit, blood chemistry assays kit, cytotoxicity assays kit.
Based on application, the market has been segmented as atherosclerosis, obesity, dyslipidemia, diabetes, angina, stroke, carotid artery disease, peripheral arterial disease, others.
Based on the end users, the market has been segmented as hospitals and clinics, pharmaceutical and biotechnological companies and others.
Regional analysis:
The Americas account for a significant market share owing to the presence of huge number of people suffering from obesity and overweight. According to the Centers for Disease Control and Prevention (2014), 73.5 million adults in the US have diagnosed with high cholesterol level. Additionally, increasing awareness among the people regarding different monitoring procedures and well developed technology has also contributed in the market growth of the LDL Test.
Europe is the second largest market in the world due to high income and encouragement by government in research and development.
Asia Pacific region is expected to grow rapidly and China and India are likely to lead this market due to fast growing healthcare sector during the forecast period.
Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. The African region is expected to witness a moderate growth owing to poor economic and political conditions and poor healthcare development.
Key Players in the LDL test Market
Some of key players profiled in the market report of LDL test are
The market report for LDL test by Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.
| Report Attribute/Metric | Details |
| Â Â Market Size 2032 | Â Â USD 15.86 Billion |
| Â Â CAGR 2032 | Â 6.44% |
| Â Â Base Year | Â Â 2023 |
| Â Â Forecast Period | Â Â 2024-2032 |
| Â Â Historical Data | Â Â 2021 |
| Â Â Forecast Units | Â Â Value (USD Billion) |
| Â Â Report Coverage | Â Â Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Â Â Segments Covered | Â Â Types, Components, Application & End Users |
| Â Â Geographies Covered | Â Â Americas, Europe, Asia-Pacific, Middle East & Africa |
| Â Â Key Vendors | Quest Diagnostics Incorporated, Sekisui Diagnostics, Express Biotech International, Randox Laboratories Ltd, Reckon Diagnostics, DiaSys Diagnostics India Private Limited, F. Hoffmann-La Roche Ltd |
| Â Â Key Market Opportunities | Â Â Increasing Prevalence of Cardiovascular Diseases |
| Â Â Key Market Drivers | Â Â Poor dietary habits and sedentary lifestyles lead to higher cholesterol levels, increasing the need for LDL tests. |
LDL Test Market Highlights:
Frequently Asked Questions (FAQ) :
LDL test market CAGR would be 6.44% during the forecast period.
LDL test market players included in the report are Express Biotech International, Quest Diagnostics Incorporated, F. Hoffmann-La Roche Ltd, Reckon Diagnostics, Randox Laboratories Ltd, DiaSys Diagnostics India Private Limited, Sekisui Diagnostics, and others.
Europe would be the second largest LDL test market.
The end users mentioned in the LDL test market report are pharmaceutical and biotechnological companies, hospitals and clinics, and others.
The types mentioned in the LDL test market report are LDL-B, LDL-P, LDL-C, and others.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
